SCHEMBL5098129

SCHEMBL5098129

N#CC=C1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1

nearest known ligand 0.61

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.61
MAOB P27338 5/20 0.56
MAOA P21397 3/20 0.56
LMNA P02545 1/20 0.56
PTGS1 P23219 1/20 0.56
CALML3 P27482 1/20 0.56
SDHA P31040 1/20 0.56
F10 P00742 13/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5098136 1.00 KCNH2 (0.61) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL5102813 0.93 KCNH2 (0.62) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL5102810 0.93 KCNH2 (0.62) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL6188971 0.92 MAOB (0.55) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL5102367 0.92 KCNH2 (0.61) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL5102364 0.92 KCNH2 (0.61) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL14145431 0.91 KCNH2 (0.60) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL14145094 0.90 KCNH2 (0.60) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL5139060 0.90 KCNH2 (0.60) KCNH2MAOBMAOALMNAPTGS1
SCHEMBL5105451 0.89 KCNH2 (0.62) KCNH2MAOBMAOALMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405228-B2 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED (IN) 2008-07-29 US claimed
US-20040063954-A1 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED 2004-04-01 US claimed
US-7405228-B2 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED (IN) 2008-07-29 US disclosed
US-7405228-B2 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED (IN) 2008-07-29 US disclosed
EP-1565461-A2 ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Patel, Mahesh V. (IN) 2005-08-24 EP disclosed
US-20040235900-A1 Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages WOCKHARDT LIMITED (IN) 2004-11-25 US disclosed
US-20040063954-A1 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED 2004-04-01 US disclosed
WO-2004007489-A2 ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WOCKHARDT LIMITED (IN) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063954-A1 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites POLRMT, RNASEL, RNASE1 KCNH2 3798/4885MAOB 2080/4885MAOA 1873/4885
US-20040235900-A1 Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages OXA1L, VIP, CYP51A1 KCNH2 2341/4885MAOB 1589/4885MAOA 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.